Orbis Medicines raised EUR 90 million in a Series A funding round led by NEA to develop their pipeline of next-generation oral macrocycle drugs.

Jan 06, 2025•12 months ago

Amount Raised

€90 Million

Round Type

series a

CopenhagenBiotechnology

Investors

ForbionNovo HoldingsExport And Investment Fund Of DenmarkCormorantEli Lilly And CompanyNea

Description

Orbis Medicines announced the close of a EUR 90 million Series A funding round, bringing their total raised to EUR 116 million. The funds will support the development of their oral macrocycle drugs, called ‘nCycles’, which aim to provide high-value alternatives to traditional biologic drugs.

Company Information

Company

Orbis Medicines

Location

Copenhagen, Capital Region Of Denmark, Denmark

About

Orbis Medicines is a biotechnology company focused on pioneering a new era for oral macrocycle drug discovery. Macrocycles are a large and diverse family of compounds with highly desirable therapeutic properties, defined by the presence of a cyclic structure. Orbis’ nGen platform is designed to systematically explore the macrocycle chemical space using a highly automated chemistry platform and deliver oral macrocycle drug candidates – nCycles – suitable for both intra- and extracellular targets. Orbis’ programs are focused on high-value oral alternatives to blockbuster biologic drugs and targets challenging for established modalities.

Related People

3 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends